Skip to search boxSkip to navigationSkip to main content

Ubc9 deficiency selectively impairs the functionality of common lymphoid progenitors (CLPs) during bone marrow hematopoiesis

  • Mohammed Abdelssalam Hassan Edrees
    ,
  • Jiahui Luo
    ,
  • Fei Sun
    ,
  • Faxi Wang
    ,
  • Long He
    ,
  • Tiantian Yue
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Abstract

Hematopoietic development occurs in the bone marrow, and this process begins with hematopoietic stem cells (HSCs). Ubc9 is a unique E2-conjugating enzyme required for SUMOylation, an evolutionarily conserved post-translational modification system. We herein show that a conditional Ubc9 deletion in the hematopoietic system caused decreased thymus weight and reduced lymphocyte to myeloid cell ratio. Importantly, Ubc9 deletion in the hematopoietic system only selectively impaired the development of common lymphoid progenitors (CLPs) in the bone marrow and perturbed their potential to differentiate into lymphocytes, thereby decreasing the number of T/B cells in the periphery. Ubc9 was found to be required for CLP viability, and therefore, Ubc9 deficiency rendered CLPs to undergo apoptosis and attenuated their proliferation. Thus, Ubc9 plays a critical role in the regulation of CLP function during hematopoietic development in the bone marrow.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 314-322 (9 pages)

Journal (Volume, Issue Number)

Molecular Immunology (Volume 114)

Publication milestones

  • Published - 10/2019

Publication status

Published - 10/2019

ISSN

0161-5890

Publication IDs

  • Scopus: 85070871779
  • PubMed: 31442915

Publication metrics

Metrics

Fractional count
1
Fractional count
0.06
Fractional count
17
Fractional count
0.94
Fractional count
1
Fractional count
1
SciVal
FWCI
0.14
SciVal
Author count
18
SciVal
Paper percentile
49
SciVal
citations
1
Scopus
citations

PlumX, opens in new tab

Captures
7
Citation count
6

Funding Details

This study was supported by the National Natural Science Foundation of China (81530024, 9174920038, 81471046, 81770823 and 81670929), the Ministry of Science and Technology (2016YFC1305002 and 2017YFC1309603), NHC Drug Discovery Program (2017ZX09304022-07), the Department of Science and Technology of Hubei State (2017ACA096), the Integrated Innovative Team for Major Human Disease Programs of Tongji Medical College, Huazhong University of Science and Technology, and the Innovative Funding for Translational Research from Tongji Hospital. This study was supported by the National Natural Science Foundation of China ( 81530024 , 9174920038 , 81471046 , 81770823 and 81670929 ), the Ministry of Science and Technology ( 2016YFC1305002 and 2017YFC1309603 ), NHC Drug Discovery Program ( 2017ZX09304022-07 ), the Department of Science and Technology of Hubei State ( 2017ACA096 ), the Integrated Innovative Team for Major Human Disease Programs of Tongji Medical College, Huazhong University of Science and Technology, and the Innovative Funding for Translational Research from Tongji Hospital.
FundersFunding numbers
Department of Science and Technology of Hubei State
-
Integrated Innovative Team for Major Human Disease Programs of Tongji Medical College
-
NHC Drug Discovery Program
2017ZX09304022-07
Tongji Medical College
-
NHC
-
NSFC
81471046, 81530024, 9174920038, 81770823, 81670929
MOST
2017YFC1309603, 2016YFC1305002
HUST
-
MICYT
-
Department of Science and Technology, Hubei Provincial People's Government
2017ACA096
TJH
-